Technical Handbooks
Dosage-form and development handbooks: for every topic, the science behind it, the critical parameters and typical limits, troubleshooting, and the compendial and ICH references. Each title can also be commissioned as a company-specific edition.
5 topics
Tablets and capsules dominate oral therapy because they are stable, dose-accurate and well accepted by patients. Their quality is governed by the properties of the powders (particle size, flow, compressibility, moisture), by the unit operations that transform them (blending, granulation, compression, coating, encapsulation) and by the tests that confirm uniformity, mechanical strength, disintegration and dissolution. A QbD approach per ICH Q8(R2) links material attributes and process parameters to these CQAs.
Powder flow is controlled by particle size and shape, density and cohesive interparticle forces (van der Waals, electrostatic and moisture-driven liquid bridges); cohesion rises sharply as particles become finer, especially below about 100 µm. Poor flow causes irregular die or dosator filling and therefore weight and content variability. Blending is a competition between convective/diffusive mixing and segregation by percolation (sifting), fluidisation and trajectory, so a well-mixed blend can de-mix during discharge and transfer. Lubricant blending is a separate, shear- and time-sensitive step: over-mixing magnesium stearate spreads a hydrophobic film over particles, lowering tablet strength and slowing dissolution.
Key points
Granulation enlarges and densifies particles to improve flow and compressibility, lock the API into granules so it cannot segregate, and reduce dust. In wet granulation the liquid passes through pendular, funicular and capillary saturation states; on drying, dissolved binder forms solid bridges, which makes the route robust for high-dose, poorly compressible APIs but exposes them to water and heat. Dry granulation (roller compaction or slugging) densifies by pressure alone and suits moisture- or heat-sensitive APIs, but the first compaction consumes part of the material's bonding capacity (loss of re-compactibility, 'work hardening'). Direct compression is the simplest and cheapest route but depends entirely on excipients with good flow and compactibility and on well-controlled API particle properties.
Key points
During compaction particles rearrange, then deform elastically, plastically or by brittle fragmentation; on decompression and ejection, stored elastic energy is released. Capping and lamination occur when this elastic recovery or entrapped air exceeds the strength of the bonds formed, sticking and picking occur when adhesion to the punch face is stronger than cohesion within the tablet, and weight variation reflects non-uniform die filling. Dwell time matters because plastic deformation and bonding are time-dependent, so faster presses expose viscoelastic materials to more defects. Tensile strength (rather than raw breaking force) allows comparison across sizes; values of roughly 1.7–2 MPa or more are usually adequate for coating, packaging and handling.
Key points
Film coating deposits a thin polymer layer, usually HPMC-, PVA- or methacrylate-based, to mask taste, improve appearance and swallowability, protect against moisture or light, or control release. Coating quality is a balance between spray rate and drying capacity: atomised droplets must reach the tablet, spread and coalesce before they dry (otherwise spray-drying and rough films result), but the surface must not be over-wetted (twinning, picking, core erosion). Plasticisers lower the glass transition and minimum film-forming temperature so that the film coalesces without cracking, and opacifiers such as titanium dioxide or iron oxides provide opacity and light protection (titanium dioxide is under regulatory review in the EU after its food-additive ban, so alternatives are increasingly evaluated). Enteric films use polymers with acidic groups that stay insoluble in gastric acid and dissolve above about pH 5.5–7 depending on the polymer.
Key points
Hard capsules (gelatin or HPMC) are filled mainly by dosator or dosing-disc (tamping) machines, both of which form a lightly compacted plug; fill-weight accuracy therefore depends on bulk density, flow, compressibility and lubricity of the powder. Gelatin shells contain about 13–16 % water, which acts as a plasticiser: they become brittle when dried out at low humidity and soft or sticky at high humidity, whereas HPMC shells contain less water (about 4–6 %) and are preferred for hygroscopic or moisture-sensitive fills. Gelatin can cross-link on exposure to aldehydes (e.g. from excipient impurities) or heat and humidity, forming a pellicle that slows dissolution; USP <711> therefore permits enzymes (pepsin or pancreatin) in the dissolution medium for gelatin capsules.
Key points
5 topics
Semi-solids (ointments, creams, gels and pastes) are applied to skin or mucosa for local or, less often, systemic action. Their performance depends on microstructure – phase type, droplet and particle size, and rheology – which controls spreadability, physical stability, drug release and skin permeation. Quality is governed by uniformity, rheology, microbial quality and preservation, and in vitro release testing per USP <1724>, within the test framework of USP <3> and Ph. Eur. monograph 0132.
Ointments are single-phase bases: hydrocarbon (white soft paraffin), absorption (wool fat, which can take up water), water-removable or water-soluble (macrogol) bases; hydrocarbon bases are occlusive, hydrate the stratum corneum and enhance penetration. Creams are emulsions – o/w 'vanishing' or w/o 'cold' creams – whose body usually comes from a lamellar gel network formed by a fatty amphiphile (cetostearyl alcohol) with a surfactant in the continuous phase. Gels are three-dimensional networks of polymers (carbomer, cellulose ethers, poloxamer) or particles that immobilise a liquid; pastes contain a high proportion of finely dispersed solids (often 20–50 %), which makes them stiff and protective. Because flux through skin is driven by the drug's thermodynamic activity in the vehicle, base choice and drug solubility in it are as important as concentration.
Key points
The hydrophile–lipophile balance (HLB, Griffin scale 0–20 for non-ionics) describes the relative size and strength of the polar and non-polar parts of a surfactant; for polyethoxylated non-ionics HLB ≈ 20 × (mass of hydrophilic part / total mass). By Bancroft's rule the phase in which the emulsifier is more soluble becomes continuous, so low-HLB (about 3–6) emulsifiers form w/o and high-HLB (about 8–18) emulsifiers form o/w emulsions. Each oil phase has a 'required HLB', matched by blending a lipophilic and a hydrophilic emulsifier; mixed emulsifiers pack into condensed interfacial films and, together with fatty alcohols, build lamellar gel networks that stabilise creams far better than a single surfactant. HLB ignores temperature, electrolytes and chemical compatibility, so it is a starting point to be confirmed experimentally.
Key points
Semi-solids are non-Newtonian: they are shear-thinning (pseudoplastic), usually show a yield stress (plastic behaviour) and are often thixotropic, recovering structure slowly after shearing. Rheology determines extrusion from the tube, spreading on skin, skin feel and physical stability, because a yield stress resists creaming and sedimentation. Homogenisation (rotor–stator or high-pressure) breaks droplets by shear and turbulence, increasing interfacial area that the emulsifier must cover; excessive shear can, however, destroy a forming gel network, degrade polymers such as carbomer and entrain air. In creams the cooling history sets the crystalline gel network, so phase temperatures, cooling rate and when shear is applied are critical process parameters.
Key points
Aqueous multi-dose semi-solids need a preservative system, and its activity depends on the free preservative concentration in the water phase rather than on the total amount added. Free concentration is reduced by partitioning into the oil phase, solubilisation in surfactant micelles (notably parabens with polysorbates), binding to polymers and sorption to packaging. Weak-acid preservatives such as sorbic and benzoic acid are active mainly in the un-ionised form, so their efficacy falls sharply as pH rises above their pKa (about 4.2–4.8). Efficacy is demonstrated by a challenge test with specified organisms, while the level is kept to the minimum effective concentration because of irritation and sensitisation.
Key points
Emulsion attributes such as droplet size, viscosity and gel-network structure depend on shear history and heat transfer, neither of which scales linearly with batch volume. As vessels get larger, the jacket area-to-volume ratio falls, so heating and especially cooling take longer and the product spends more time in shear-sensitive temperature windows; mixer tip speed, power per volume, circulation time and homogeniser turnover also change. Scale-up therefore keeps geometric similarity where possible and matches the parameters that govern the critical attributes – tip speed for droplet break-up, total shear exposure, and the cooling profile, which is often the most critical for creams. FDA SUPAC-SS defines the documentation and tests (including IVRT) required for batch-size, equipment and process changes.
Key points
5 topics
Oral liquids — solutions, syrups, suspensions and emulsions — give dose flexibility for paediatric, geriatric and dysphagic patients but are chemically, physically and microbiologically less forgiving than solid dosage forms. Their quality is governed by chemical stability in an aqueous medium, physical stability (crystallisation, sedimentation, caking), palatability, accuracy of the delivered dose and microbial control through preservation and water quality.
In a solution the drug is molecularly dispersed, so hydrolysis, oxidation and other pH-dependent reactions proceed far faster than in the solid state; formulation therefore starts from the drug's pH–rate and pH–solubility profiles. Syrups are concentrated sucrose or polyol solutions: Syrup NF (85% w/v sucrose, about 65% w/w) has such low water activity that it resists microbial growth, but any dilution removes this osmotic self-preservation. Under acidic conditions and heat sucrose inverts to glucose and fructose, which can brown by caramelisation or by Maillard reaction with amine drugs, and near-saturated syrups crystallise at the bottle neck (cap-locking).
Key points
Suspensions are thermodynamically unstable coarse dispersions whose settling velocity follows Stokes' law, v = 2r²(ρs − ρl)g / 9η: halving the particle radius cuts velocity four-fold, while reducing the density difference or raising vehicle viscosity slows it proportionally. A deflocculated system settles slowly but packs into a dense sediment that cakes and resists redispersion, whereas controlled flocculation (electrolytes, ionic surfactants or bridging polymers) gives loose floccules with a high sedimentation volume that redisperse on gentle shaking. Robust products combine controlled flocculation with a shear-thinning structured vehicle that has a yield value, and also control crystal growth (Ostwald ripening, temperature cycling, polymorphic conversion) that shifts the particle size distribution during storage.
Key points
For poorly water-soluble drugs the main tools are pH adjustment or salt selection, cosolvents, micellar solubilisation and cyclodextrin complexation. For a weak base S = S0(1 + 10^(pKa − pH)), so solubility rises about ten-fold per pH unit below the pKa until the salt's own solubility limit (pHmax) is reached; for a weak acid the relationship is mirrored above the pKa. Cosolvents raise solubility roughly log-linearly with cosolvent fraction (log Sm = log Sw + σf), so dilution in the GI tract or an infusion bag can lower solubility faster than concentration and precipitate the drug, whereas micellar and 1:1 cyclodextrin (AL-type) systems lose capacity roughly linearly and tolerate dilution better.
Key points
Bitterness is perceived when dissolved drug reaches taste-receptor cells (TAS2R bitter receptors), so in a liquid—where the drug is already partly in solution—the most effective strategies reduce the free dissolved fraction: a poorly soluble salt or form formulated as a suspension, pH adjusted to suppress ionisation-driven solubility, complexation with cyclodextrins or ion-exchange resins, or polymer-coated particles in powders for reconstitution. Sweeteners, flavours, cooling agents and viscosity only modify perception and are rarely sufficient for intensely bitter drugs. Palatability is a regulatory expectation for paediatric medicines because poor acceptability directly causes dosing failure.
Key points
Aqueous oral liquids are non-sterile but readily support microbial growth, so quality rests on low-bioburden raw materials and water, hygienic manufacture and—for multidose products—an effective preservative system. Ph. Eur. 5.1.4 sets for aqueous oral preparations TAMC 10² CFU/mL, TYMC 10¹ CFU/mL and absence of Escherichia coli in 1 mL; non-aqueous oral preparations are allowed 10³ and 10² CFU per g or mL. Preservative activity depends on the unbound, usually un-ionised fraction: benzoic and sorbic acids are active only at acidic pH, and parabens lose activity by partitioning into micelles, oils and polymers or by sorption to packaging.
Key points
5 topics
Sterile dosage forms bypass the body's barrier defences, so they must be sterile, practically free from visible particles, within limits for subvisible particles and bacterial endotoxins, and physiologically compatible in tonicity and pH. Sterility cannot be tested into a product: it is assured by process design—terminal sterilisation wherever possible, otherwise validated aseptic processing under a documented contamination control strategy (EU GMP Annex 1, 2022)—and by container closure integrity throughout shelf life.
Route determines the formulation window: intravenous products are diluted rapidly by blood and tolerate a wider range of pH and osmolality, intramuscular and subcutaneous injections are limited in volume and must avoid irritation, and intrathecal, epidural and intraocular products must be preservative-free, isotonic and close to neutral. Ophthalmic drops (≈ 30–50 µL) exceed the capacity of the conjunctival sac, so most of the dose drains through the nasolacrimal duct and ocular bioavailability is typically below 5%; viscosity enhancers, in-situ gelling polymers and suspensions are used to prolong residence. Multidose parenteral and ophthalmic products need an antimicrobial preservative or a container that prevents contamination, and the preservative must meet the stricter parenteral/ophthalmic criteria of Ph. Eur. 5.1.3.
Key points
Osmolality is a colligative property measured by freezing-point depression (USP <785>, Ph. Eur. 2.2.35); plasma is about 285–295 mOsm/kg, and 0.9% sodium chloride and 5% glucose are approximately isotonic. Tonicity is the effective osmotic pressure across a particular membrane, so solutes that permeate red cells (urea, glycerol, boric acid) can be iso-osmotic yet haemolytic; hypotonic injections cause haemolysis and hypertonic ones pain, crenation and phlebitis. pH and buffer choice balance chemical stability and solubility against physiological tolerance: use the lowest buffer capacity that still holds pH over shelf life, so that blood or tears neutralise the dose quickly after administration.
Key points
Regulators expect terminal sterilisation in the final container whenever the product tolerates it; the EMA decision trees allow lower-F0 cycles, and then sterilising filtration with aseptic processing, only with justification. Moist heat is the reference method (121 °C for 15 min), quantified by F0—equivalent minutes at 121.1 °C with z = 10 °C—and designed for a sterility assurance level (SAL) of ≤ 10⁻⁶; dry heat (also used for depyrogenation), ionising radiation (25 kGy reference dose) and ethylene oxide serve heat-sensitive materials. Aseptic processing cannot be assured by end-product testing, so EU GMP Annex 1 (2022) requires a site-wide contamination control strategy, Grade A critical zones with unidirectional airflow (preferably RABS or isolators), validated sterilising filtration and periodic aseptic process simulation.
Key points
Freeze-drying removes water by sublimation of ice (primary drying) and desorption of unfrozen bound water (secondary drying), giving a stable cake for drugs and biologics that degrade in solution. The critical formulation temperature is the collapse temperature (Tc), usually a few degrees above Tg′ (the glass transition of the maximally freeze-concentrated amorphous phase) or the eutectic temperature (Teu) of a crystalline solute, and product temperature during primary drying must stay below it. Product temperature is not set directly: it results from shelf temperature and chamber pressure through the vial heat-transfer coefficient (Kv) and the dry-layer resistance (Rp), so formulation, freezing protocol and cycle must be designed together.
Key points
Particles in injections are classed as extrinsic (environment, fibres, insects), intrinsic (from process or packaging: glass, rubber, stainless steel, silicone oil) and inherent (product-related, e.g. protein aggregates); visible particles must be essentially absent (100% inspection) and subvisible particles are counted against compendial limits because they can occlude capillaries and provoke inflammation or immunogenicity. Glass delamination, rubber coring and silicone-oil droplets are recurring intrinsic sources linked to formulation pH and buffer, sterilisation and device design. Container closure integrity (CCI) maintains sterility over shelf life and is best verified with deterministic methods—vacuum decay, high-voltage leak detection, headspace gas analysis—rather than probabilistic dye or microbial ingress tests (USP <1207>).
Key points
4 topics
Biological products — recombinant proteins, monoclonal antibodies, peptides, vaccines and blood-derived products — are large, conformationally fragile molecules whose activity depends on an intact higher-order structure. Their quality is defined not by a single assay value but by a profile of purity, potency, aggregates, charge and size variants and particles that must be maintained from drug substance through fill-finish, storage, transport and administration. ICH Q5C and ICH Q6B set the framework for their stability programmes and specifications.
Proteins degrade by physical routes (unfolding, aggregation, adsorption, precipitation) and chemical routes (deamidation, isomerisation, oxidation, hydrolysis, disulfide scrambling, glycation), and the two are coupled: a chemically modified molecule often unfolds or aggregates more readily. Asparagine deamidation — fastest in Asn-Gly and Asn-Ser sequences via a succinimide intermediate — accelerates at neutral to alkaline pH, whereas aspartate isomerisation and Asp-Pro cleavage dominate under mildly acidic conditions, so formulation pH is always a compromise between pathways. Methionine and tryptophan oxidation is driven by peroxides (often from polysorbate), trace metals and light. Because protein unfolding does not follow simple Arrhenius kinetics, ICH Q5C requires real-time, real-temperature data for shelf-life assignment; accelerated and stress studies map degradation pathways rather than support extrapolation.
Key points
Buffer and excipient selection controls the conformational and colloidal stability of a protein: pH sets the net charge, protein–protein interactions and the rates of chemical degradation, while sugars, polyols and some amino acids stabilise the native state by preferential exclusion from the protein surface. In lyophilised products, non-reducing disaccharides such as sucrose and trehalose also protect by forming an amorphous glass and replacing the hydrogen bonds of water during drying. Each excipient brings its own liabilities — phosphate crystallisation on freezing, citrate injection-site pain, glycation by reducing sugars, polysorbate degradation — and its choice and level must be justified in pharmaceutical development (ICH Q8(R2)).
Key points
Protein aggregates range from reversible dimers to insoluble visible particles and are a primary immunogenicity concern, because repetitive, partially unfolded epitopes can break immune tolerance and induce anti-drug antibodies. Aggregation proceeds through partially unfolded intermediates (conformational), through native self-association at high concentration (colloidal), and especially at interfaces — air–liquid, ice–liquid, silicone oil and container surfaces — where adsorbed molecules unfold and are shed back into solution as aggregates. At low concentration the same adsorption causes measurable loss of dose to glass, plastics, filters and infusion lines, so surface-to-volume ratio and contact materials must be studied rather than assumed inert.
Key points
Most biologics and vaccines are labelled for 2–8 °C, and some for frozen (≤ −20 °C) or ultra-low (−90 to −60 °C) storage; both heat exposure and accidental freezing can damage them irreversibly. Heat accelerates aggregation and chemical degradation cumulatively, whereas a single freezing event can destroy aluminium-adjuvanted vaccines and many liquid proteins — and freezing during storage and transport is at least as common a failure as overheating. A cold chain is therefore a validated system of qualified equipment, temperature-mapped storage areas, qualified shippers, calibrated monitoring and documented excursion management, governed by good distribution practice and USP <1079>, not simply a refrigerator.
Key points
4 topics
Vitamin and mineral products combine many ingredients whose doses differ by five to six orders of magnitude — from micrograms of vitamin B12 or selenium to hundreds of milligrams of calcium or magnesium — and many of them are chemically labile or react with one another. Quality depends on expressing nutrient content correctly (chemical form, unit and elemental basis), on justified overages that keep every nutrient at or above label claim throughout shelf life without exceeding safe upper limits, and on content uniformity of micro-dosed nutrients achieved through sound premix design.
Label claims are expressed per active vitamin (retinol, cholecalciferol, α-tocopherol, folate and so on), while manufacturers buy esters, salts and diluted commercial forms — beadlets, dry powders, oily solutions and triturations — whose potency is stated in IU/g or % on the certificate of analysis. Calculation errors arise when the molecular weight of the ester or salt, the stereochemistry (natural d- versus synthetic dl-tocopherol) or the unit system (IU versus µg RAE, mg α-tocopherol, µg DFE) is ignored. Every formula calculation should start from the label unit, convert to the reference compound, and then divide by the actual assay of the commercial lot.
Key points
An overage is a deliberate excess of a nutrient above label claim, added to compensate for losses during manufacture and degradation over shelf life. Labile vitamins — A, D, C, B1, B12 and folic acid — degrade by oxidation, hydrolysis, light and interaction with minerals and other vitamins, so unprotected multivitamins can lose a substantial fraction of their most sensitive nutrients before expiry. Overages must be justified by development and stability data (ICH Q8(R2) for medicines; for supplements, label claims must be met throughout shelf life, e.g., 21 CFR 101.9(g)), and must not push release values above the upper specification or intake above safe upper limits.
Key points
Minerals are dosed and labelled as the element (elemental calcium, iron, zinc), but they are added as salts, oxides or chelates whose elemental fraction ranges from under 10 % to about 80 %. The choice of compound determines tablet mass, solubility and bioavailability, taste and gastrointestinal tolerance, hygroscopicity and reactivity towards vitamins. Calculations must use the exact hydrate form and the lot assay, and mineral sources must be controlled for elemental contaminants such as lead, arsenic, cadmium and mercury.
Key points
A premix is a pre-blended concentrate of micronutrients, usually on an inert carrier, that is added to the final formulation — tablet or capsule blend, powder sachet or fortified food — at a fixed rate. Its purpose is to turn microgram-level ingredients into a mass that can be weighed accurately and distributed uniformly, and to separate or protect mutually reactive nutrients. Content uniformity is ultimately limited by particle statistics — each dose must contain enough particles of every micro-ingredient — and by segregation driven by differences in particle size, density and shape.
Key points
4 topics
Scale-up and technology transfer cover the path of a formulation from development batches to commercial manufacture, at the same or another site. Quality here is governed by a science- and risk-based understanding of how equipment, scale and process parameters affect critical quality attributes (ICH Q8–Q10), confirmed by a lifecycle approach to process validation and documented knowledge transfer between sending and receiving units.
Scale-up is not a simple multiplication of batch size: heat and mass transfer, shear, residence time and powder flow change with equipment geometry, so the aim is to keep the product's critical quality attributes constant rather than the set-points. ICH Q1A(R2) and SUPAC-IR define a pilot batch as at least one-tenth of full production scale or 100,000 tablets/capsules, whichever is larger, and registration batches (primary stability, biobatch) are normally made at this scale using the same operating principle as commercial equipment. Scaling rules based on dimensionless or equipment-independent quantities (impeller tip speed, Froude number, spray rate per unit bed area or per gun, compression dwell time) give starting points that are then confirmed by limited DoE or trial runs at the larger scale.
Key points
ICH Q8(R2) defines a critical process parameter (CPP) as a process parameter whose variability has an impact on a critical quality attribute (CQA) and therefore should be monitored or controlled to ensure the process produces the desired quality. CPPs are identified by linking the QTPP and CQAs to each unit operation through risk assessment (ICH Q9(R1) tools such as Ishikawa diagrams and FMEA) and then confirming the impact experimentally with design of experiments (DoE). Criticality reflects the degree of impact on CQAs, not importance for yield or throughput; parameters that affect only process performance (in industry terms, key or non-critical parameters) are controlled through the GMP system.
Key points
FDA's guidance 'Process Validation: General Principles and Practices' (2011) treats validation as a three-stage lifecycle: Stage 1 Process Design (building process knowledge and the control strategy), Stage 2 Process Qualification (qualification of facility, utilities and equipment, followed by process performance qualification, PPQ, at commercial scale) and Stage 3 Continued Process Verification (CPV) for ongoing assurance in routine production. EU GMP Annex 15 (2015) and the EMA process validation guideline accept traditional, continuous and hybrid approaches; the number of PPQ batches must be justified by process knowledge and variability, and three consecutive batches remain the common default for traditional validation of conventional processes. PPQ batches are made under routine conditions by routine personnel but with enhanced sampling and testing, and should be completed before commercial distribution (concurrent validation only where justified).
Key points
Technology transfer is a logical, documented procedure for moving a process together with its documentation and professional expertise between development and manufacture or between manufacturing sites; WHO TRS 961 Annex 7 frames it as a project between a sending unit (SU) and a receiving unit (RU) with defined responsibilities, a gap analysis and pre-agreed acceptance criteria. ICH Q10 treats technology transfer as a lifecycle stage and knowledge management as an enabler, so the package must carry not only the recipe but its rationale (development report, risk assessments, control strategy and known failure modes). Success is demonstrated by comparing RU output with SU history and the specification, followed by PPQ at the RU and, where applicable, a regulatory variation.
Key points
4 topics
Analytical methods and stability studies provide the evidence that every batch meets its specification at release and throughout its shelf life. Quality here is governed by fit-for-purpose procedures managed across their lifecycle (ICH Q2(R2)/Q14), a discriminating dissolution test, stability programmes designed per ICH Q1A(R2) for the target climatic zones, and specifications and impurity limits justified per ICH Q6A, Q3A/Q3B and M7.
ICH Q14 (adopted in 2023 together with Q2(R2)) starts analytical procedure development from an analytical target profile (ATP) stating what must be measured, over what range and with what accuracy and precision; the enhanced approach adds risk assessment, multivariate robustness studies and, where useful, a method operable design region (MODR). ICH Q2(R2) then sets the validation characteristics according to the procedure's purpose: specificity/selectivity, working range (with response/linearity), accuracy, precision (repeatability and intermediate precision), and detection/quantitation limits for impurity tests. Validation demonstrates fitness over the reportable range, and system suitability tests protect the method at every run.
Key points
Dissolution testing per USP <711>/Ph. Eur. 2.9.3 is both a batch-release quality control test and, when discriminating, a surrogate for in vivo performance. Method development per USP <1092> selects apparatus, medium, volume and agitation from the drug's solubility over the physiological pH range 1.2–6.8, aiming for sink conditions (medium volume at least three times that required to form a saturated solution) and a method that detects meaningful changes in formulation and process (e.g., particle size, hardness, lubrication). Profile comparison by the similarity factor f2 underpins SUPAC changes, additional-strength waivers and BCS-based biowaivers (ICH M9).
Key points
ICH Q1A(R2) requires stability data on at least three primary batches of the drug product, at least two of them at least pilot scale, made by a process simulating the commercial one and packed in the proposed container closure system. Storage conditions follow the climatic zone: long-term 25 °C/60 % RH or 30 °C/65 % RH, with 30 °C/75 % RH required by WHO for zone IVb countries; accelerated 40 °C/75 % RH for 6 months; and intermediate 30 °C/65 % RH when significant change occurs at accelerated and the long-term condition is 25 °C/60 % RH. Shelf life is assigned from long-term data evaluated statistically per ICH Q1E, with extrapolation only within the limits that guideline allows.
Key points
ICH Q6A defines a specification as a list of tests, references to analytical procedures and acceptance criteria to which a drug substance or drug product should conform; it confirms quality but is only one part of the control strategy and should be set from data on clinical/stability batches, analytical variability and stability trends. Organic impurities are controlled by the ICH Q3A(R2) (drug substance) and Q3B(R2) (degradation products in drug product) thresholds, which depend on the maximum daily dose, while residual solvents (Q3C), elemental impurities (Q3D) and DNA-reactive (mutagenic) impurities including nitrosamines (M7) have their own risk-based limits. Release and shelf-life acceptance criteria may differ when justified (e.g., a tighter assay limit at release to allow for degradation).
Key points